|Bid||12.00 x 1000|
|Ask||18.75 x 1800|
|Day's Range||13.38 - 14.08|
|52 Week Range||12.86 - 41.36|
|Beta (3Y Monthly)||3.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.17|
CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of $1.93 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
SAN DIEGO, Oct. 24, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 23) Amarin Corporation plc (NASDAQ: AMRN ) Imprimis Pharmaceuticals ...
SAN DIEGO, Oct. 18, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
Anyone researching La Jolla Pharmaceutical Company (NASDAQ:LJPC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...